Structure-Based Design, Optimization, and Development of [F]LU13: A Novel Radioligand for Cannabinoid Receptor Type 2 Imaging in the Brain with PET.

The cannabinoid receptor type 2 (CB2R) is an attractive target for the diagnosis and therapy of neurodegenerative diseases and cancer. In this study, we aimed at the development of a novel F-labeled radioligand starting from the structure of the known naphthyrid-2-one CB2R ligands. Compound () was identified with the highest binding affinity and selectivity versus CB1R (CB2R = 0.